{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:47:35Z","timestamp":1776743255523,"version":"3.51.2"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.12.008","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:12:20Z","timestamp":1765818740000},"page":"e511-e524.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3280-7464","authenticated-orcid":false,"given":"Arne","family":"Strotmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6317-0216","authenticated-orcid":false,"given":"Paolo","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-5884","authenticated-orcid":false,"given":"Alexander","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Seib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-8947","authenticated-orcid":false,"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0001","first-page":"3","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci"},{"issue":"5","key":"10.1016\/j.clml.2025.12.008_bib0002","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.008_bib0004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.12.008_bib0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2025.12.008_bib0007","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2025.12.008_bib0008","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blade","year":"2005","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.clml.2025.12.008_bib0009","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.008_bib0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0011","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2025.12.008_bib0012","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5500\/wjt.v6.i2.321","article-title":"First line vs delayed transplantation in myeloma: certainties and controversies","volume":"6","author":"Brioli","year":"2016","journal-title":"World J Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.12.008_bib0014","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0015","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705360","article-title":"High-dose melphalan (200\u2009mg\/m2) supported by autologous stem cell transplantation is safe and effective in elderly (\u2a7e65 years) myeloma patients: comparison with younger patients treated on the same protocol","volume":"37","author":"Jantunen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","article-title":"Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"52","author":"Muta","year":"2013","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.clml.2025.12.008_bib0017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/bmt.2015.106","article-title":"High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma","volume":"50","author":"Wildes","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/bmt.2014.255","article-title":"Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years","volume":"50","author":"Auner","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clml.2025.12.008_bib0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"issue":"26","key":"10.1016\/j.clml.2025.12.008_bib0020","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2025.12.008_bib0021","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.clml.2025.12.008_bib0022","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/cncr.33831","article-title":"Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2025.12.008_bib0023","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.12.008_bib0024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbmt.2013.12.557","article-title":"Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma","volume":"20","author":"Saad","year":"2014","journal-title":"Biol Blood Marrow Trans"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/bmt.2008.300","article-title":"Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center","volume":"43","author":"Guilfoyle","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.1016\/j.clml.2025.12.008_bib0026","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0027","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41409-020-01026-7","article-title":"Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0028","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic cell transplantation\u2013specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2025.12.008_bib0029","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbmt.2008.06.019","article-title":"Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"14","author":"Labont\u00e9","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/bmt.2014.155","article-title":"The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma","volume":"49","author":"Jaglowski","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2025.12.008_bib0031","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with Myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.008_bib0032","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2014.07.013","article-title":"Older patients with myeloma derive similar benefit from autologous transplantation","volume":"20","author":"Sharma","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2025.12.008_bib0033","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bbmt.2013.04.027","article-title":"Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age","volume":"19","author":"McCarthy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"10.1016\/j.clml.2025.12.008_bib0034","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.clml.2025.12.008_bib0035","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.3324\/haematol.2021.279179","article-title":"Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2025.12.008_bib0036","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.008_bib0037","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.12.008_bib0038","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ctr.12762","article-title":"Effect of melphalan 140 mg\/m2 vs 200 mg\/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation\u2014a single center experience","volume":"30","author":"Katragadda","year":"2016","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0039","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.008_bib0040","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41409-018-0379-y","article-title":"Melphalan dose in myeloma patients \u226565 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study","volume":"54","author":"Ghilardi","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0041","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-018-3528-x","article-title":"Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"98","author":"Marini","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0042","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0043","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.12.008_bib0044","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2025.12.008_bib0046","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.12.008_bib0047","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2025.12.008_bib0048","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.12.008_bib0049","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2025.12.008_bib0050","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.clml.2025.12.008_bib0051","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.12.008_bib0052","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clml.2025.12.008_bib0053","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1093\/oncolo\/oyac067","article-title":"Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma","volume":"27","author":"Jakubowiak","year":"2022","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.clml.2025.12.008_bib0054","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","article-title":"Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study","volume":"24","author":"Gordan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.clml.2025.12.008_bib0055","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.12.008_bib0056","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/17474086.2021.1983426","article-title":"Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients","volume":"14","author":"Tacchetti","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.008_bib0057","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis","volume":"39","author":"Facon","year":"2022","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.12.008_bib0058","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.clml.2025.12.008_bib0059","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:18:08Z","timestamp":1776741488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025043034"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}